Dexamfetamine: Discovery, Development, Safety and Pharmacovigilance
Dexamfetamine illustrates why a familiar pharmacological family still requires precise product identification. The active substance is the dextrorotatory enantiomer of amfetamine; US sources generally call it dextroamphetamine. Its clinical history overlaps with racemic amfetamine, but evidence for one enantiomer, a mixture, a release formulation or a prodrug cannot simply be transferred to every other presentation.
This article follows the development of the medicine into current clinical and regulatory practice. It then examines how professionals can evaluate safety reports without confusing therapeutic exposure, medication errors, nonmedical use and findings from broader stimulant populations. The companion amfetamine lifecycle article covers the racemate and wider historical context.
- Dexamfetamine: Discovery, Development, Safety and Pharmacovigilance
- Active substance, stereochemistry and product identity
- Discovery and the development of a therapeutic product
- Pharmacology and the importance of exposure over time
- Clinical development and interpretation of benefit
- Authorisation, treatment guidance and regional differences
- Safety during therapeutic treatment
- Misuse, dependence, diversion and withdrawal
- Pregnancy, lactation and evidence interpretation
- Translating the evidence into pharmacovigilance practice
- Signal evaluation, governance and inspection evidence
- Key Takeaways
- References
- Regulatory Note
Active substance, stereochemistry and product identity
Enantiomers have the same molecular connectivity but different spatial arrangements. Dexamfetamine is therefore a distinct stereochemical subject, rather than a brand synonym for every amfetamine product. The sulfate is a salt presentation of the active substance. A salt strength, free-base amount and amount of a chemically different prodrug must not be treated as interchangeable numbers [1,2].
| Product description | What it identifies | Consequence for evidence interpretation |
|---|---|---|
| Dexamfetamine / dextroamphetamine | The dextrorotatory amfetamine enantiomer | Establish the salt, dosage form and release characteristics |
| Racemic amfetamine | A mixture of the two enantiomers | Do not relabel racemate studies as dexamfetamine-only evidence |
| Mixed amfetamine salts | A product with a defined composition | Confirm its label rather than inferring composition from a colloquial name |
| Lisdexamfetamine | A prodrug converted to dexamfetamine | Record the administered prodrug and its own formulation and dose |
These distinctions determine what a case actually describes. A patient who says “I changed my stimulant” has provided a useful starting point, but not enough information to assess equivalence of exposure. Obtain the original and replacement packs or prescription records where possible. Preserve the reported name while documenting any subsequently confirmed active-substance identification.
Discovery and the development of a therapeutic product
The parent amfetamine chemistry preceded the modern clinical-trial framework. The historical review by Heal and colleagues traces the progression from early amfetamine development to Smith, Kline and French's marketing of the more centrally potent dextrorotatory isomer as Dexedrine in 1937 [3]. This was a selection within an established chemical family, rather than the discovery of a new biological target through a contemporary development programme.
Later pharmaceutical development diversified the ways of delivering stimulant activity, including prolonged-release products and the lisdexamfetamine prodrug [3]. The business history matters chiefly because the original discovery programme, later presentation developers and current authorisation holders need not be the same organisation. A historical brand establishes neither today's ownership nor a universal current indication.
The modern evidence base consequently combines older comparative trials, later formulation research and post-marketing epidemiology. Its development therefore cannot be represented as a single modern phase I–III sequence. Longevity on the market also leaves unanswered questions about long-term outcomes and exposure in populations poorly represented in trials.
Pharmacology and the importance of exposure over time
Dexamfetamine acts through catecholaminergic systems, with effects on dopamine and noradrenaline signalling [3,4]. Mechanistic work on amfetamine has investigated both plasma-membrane transporters and vesicular monoamine handling. Freyberg and colleagues used genetic, pharmacological and optical methods in Drosophila dopamine neurons to study the vesicular component [4]. Such experiments help explain drug action; they are not direct estimates of clinical benefit, human neurotoxicity or adverse-reaction frequency.
For clinical safety assessment, the relationship between dosing time and the event is often more informative than a total daily dose alone. Record when each dose was taken, when symptoms began, whether another dose followed and when symptoms resolved. A plasma elimination half-life is not identical to the duration of perceived benefit. Nor does the end of a patient's useful symptom control establish complete drug elimination.
The prodrug comparison is particularly instructive. In Dolder and colleagues' randomised crossover study in 24 healthy volunteers, equimolar oral lisdexamfetamine and dexamfetamine exposures produced later onset and peak timing with the prodrug, but similar peak concentrations, overall exposure and several peak subjective effects [5]. The study used a single relatively high dose and was not a routine ADHD effectiveness trial. It therefore challenges an unqualified claim that a prodrug always prevents oral misuse, while providing no general clinical dose-conversion instruction or proof that all routes have equivalent risk.
Clinical development and interpretation of benefit
Paediatric comparative trials
Efron and colleagues' 1997 double-blind crossover study included 125 children receiving methylphenidate and dexamfetamine in successive two-week periods. Both improved symptoms; some teacher-rated measures favoured methylphenidate, and parent global improvement was reported for 73% and 69%, respectively [6]. These are short-term comparative findings, not evidence that one treatment is superior for every child or that either changes adult functional outcomes.
The associated tolerability paper is valuable because symptoms were measured before treatment as well as during exposure. Many apparent “side effects” were already present at baseline; dexamfetamine increased the severity of insomnia and appetite suppression relative to baseline [7]. For pharmacovigilance, this supports recording pre-existing symptoms rather than assuming that every post-treatment behavioural complaint began with the medicine.
Ramtvedt and colleagues subsequently reported short-term benefit from considering both methylphenidate and dextroamphetamine in stimulant trials: group-level superiority was not established, but individual responses could differ [8]. An average comparative result therefore cannot replace an individual assessment of benefit and tolerability. This is also why a report of inadequate effect after switching needs context, rather than an immediate assumption of product failure.
The 2026 twelve-month comparison
Poulton and colleagues randomised 100 stimulant-naïve children and adolescents to immediate-release dexamfetamine or methylphenidate, followed by clinically indicated adjustments over twelve months. They found no significant between-group symptom difference; weight loss at three months was greater with dexamfetamine, with mean changes of −1.44 kg versus −0.31 kg [9].
Interpretation requires attention to the protocol. The study was open label, had incomplete outcome data and did not perform a formal intention-to-treat analysis. Switching from dexamfetamine to lisdexamfetamine counted as remaining on the allocated treatment. Thus, the reported twelve-month persistence is not twelve months of unchanged immediate-release dexamfetamine exposure. The nonsignificant persistence comparison also does not prove equivalence. These limitations matter when applying the paper to formulation-specific safety questions.
Adult evidence and its boundaries
Paterson and colleagues' 1999 placebo-controlled study found a short-term therapeutic response to dexamfetamine in adults with ADHD; weight loss was the significant reported adverse effect [10]. The study excluded current major mood disturbance and substance abuse. Its results cannot establish safety in those excluded groups, nor do they by themselves establish long-term effectiveness or a marketing authorisation for adult ADHD in another country.
Taken together, the clinical studies support therapeutic activity while leaving important differences in patient selection, duration and comparator design. They should be read alongside the actual product information and treatment guidance, rather than used to construct an unrestricted class indication.
Authorisation, treatment guidance and regional differences
The UK product information for Amfexa, updated on emc on 5 May 2026, indicates treatment as part of a comprehensive programme for ADHD in children and adolescents aged 6–17 years after a clinically inadequate response to methylphenidate. It specifies specialist supervision [1]. The selected US dextroamphetamine sulfate tablet label lists narcolepsy and attention deficit disorder with hyperactivity in paediatric patients aged 3–16 years [2]. These are product-specific examples, not a complete inventory of nationally authorised presentations.
NICE NG87 separately recommends considering dexamfetamine for adults who respond to lisdexamfetamine but cannot tolerate its longer effect profile [11]. A clinical recommendation and a product's authorised indication answer different questions. The UK paediatric indication above does not become an adult indication merely because a guideline discusses adult use.
| Evidence or document | Question it answers | What it does not establish |
|---|---|---|
| National product information | Authorised indication and product-specific instructions | An identical licence in every jurisdiction |
| NICE recommendation | A treatment option in a defined clinical sequence | An amendment to a marketing authorisation |
| Randomised trial | Outcomes under its actual protocol | Universal eligibility or unrestricted substitution |
| Observational study | Associations in its defined population | Causation or a precise risk for every formulation |
| Safety communication | The regulator's stated concern and action | Identical absolute risks across the whole class |
For EU work, confirm the relevant national product information and local authorisation particulars. The UK example is useful for comparison but is not evidence of an EU-wide centralised authorisation. A practical regulatory inventory should retain jurisdiction, exact product, document date and indication. This makes later expectedness assessments reproducible when labels change.
Safety during therapeutic treatment
The selected US label highlights serious cardiac disease, blood-pressure and pulse increases, psychotic or manic symptoms, growth suppression, seizures and peripheral vasculopathy including Raynaud's phenomenon. It also addresses serotonin syndrome and interactions involving serotonergic agents, monoamine oxidase inhibitors, CYP2D6 inhibition and agents affecting urinary pH [2]. These warnings should not be converted into invented product-specific incidence estimates.
The UK SmPC describes baseline cardiovascular and psychiatric assessment and ongoing growth, appetite, pulse and blood-pressure review; it also gives product-specific precautions, including the MAO-inhibitor restriction [1]. This article is not a replacement for its complete contraindications, monitoring instructions or interaction section.
Cardiovascular findings in context
Cooper and colleagues studied 1,200,438 children and young adults aged 2–24 years across several ADHD medicines. Current use was not associated with a statistically significant increase in serious cardiovascular events, but the confidence interval could not exclude an approximately doubled relative risk [12]. This is an important distinction: absence of a detected association is not proof of zero risk.
The exposure category included different medicines, so the result is not a dexamfetamine-specific incidence study. Its relatively rare serious endpoints also differ from common clinical observations such as an increased pulse. Consequently, a patient-level report of exertional chest pain, syncope or an arrhythmia still requires clinical evaluation and an adequately documented phenotype. A reassuring population analysis does not explain an individual event.
Recommended follow-up should distinguish a measured abnormality from a symptom description. Record baseline and event vital signs, any established diagnosis, relevant investigations, prior cardiac disease, family history where available and the exposure timeline. State which information was reported and which interpretation comes from medical review.
Psychiatric symptoms, sleep and growth
Moran and colleagues' 2019 claims-based cohort compared new methylphenidate and amfetamine-class treatment in adolescents and young adults. Psychosis defined by a diagnosis and antipsychotic prescription was more frequent in the amfetamine group, with a hazard ratio of 1.65 (95% CI 1.31–2.09) [13]. This is an observational association across an exposure group, not a randomised estimate for dexamfetamine alone.
Clinical review should therefore describe the actual symptoms, diagnosis, timing, sleep, other medicines and substance exposure. “Behaviour change” does not establish psychosis; equally, a known psychiatric history does not exclude a treatment contribution. Retain both possibilities until the evidence supports a more specific assessment.
Growth concerns likewise require a trajectory. A single low weight cannot distinguish baseline constitution from a change following treatment. Seek dated height and weight measurements, appetite history, dose changes, treatment interruptions and clinically relevant alternatives. The baseline symptom findings in the Efron tolerability study and the weight signal in the 2026 trial reinforce different parts of this assessment [7,9]; neither supplies a lifelong risk estimate.
Interactions and changed exposure
When a reaction follows an added medicine, construct a single chronology containing both treatments. Identify the suspected interaction mechanism from the applicable label, rather than relying on a generic interaction alert. For example, the US information addresses both serotonergic combinations and factors that can alter exposure [2]. The occurrence of agitation alone is insufficient to diagnose serotonin syndrome.
A useful case assessment separates the observed findings, the treating clinician's diagnosis and the reporter's causal opinion. This allows an evolving report to be updated without retroactively presenting an initially uncertain syndrome as confirmed. The same discipline applies when a pharmacist discovers that a replacement product had a different release profile.
Misuse, dependence, diversion and withdrawal
FDA's 11 May 2023 communication required consistent class-wide warnings about misuse, abuse, addiction and overdose, including the risks of sharing prescribed stimulants. It advised risk assessment, education, secure storage, appropriate disposal and continued monitoring [14]. This was a US regulatory action, not an instruction to assign the same probability of harm to every stimulant or every patient.
Operationally, distinguish the circumstances of exposure. A prescribing error, accidental extra dose, deliberate nonmedical use, diversion to another person and a withdrawal complaint involve different narratives. They can overlap, but should not be collapsed into a single unexplained term. Document intent only when it is reported or reasonably established; do not infer addiction from an early refill request alone.
For a discontinuation report, seek the prior dose, duration, last administration, reason for stopping, subsequent symptoms and clinical assessment. Recurrence of the treated disorder, a withdrawal syndrome and an unrelated illness are competing explanations. Record the reporter's account faithfully and preserve uncertainty where the available evidence cannot distinguish them.
Pregnancy, lactation and evidence interpretation
Huybrechts and colleagues' international cohort found no increased adjusted risk of major or cardiac malformations with the studied first-trimester amfetamine exposures: adjusted relative risks were 1.05 (95% CI 0.93–1.19) and 0.96 (0.78–1.19), respectively [15]. This does not establish absence of all reproductive risk, and the exposure group is not synonymous with a single dexamfetamine formulation.
Cohen and colleagues examined a different question: placental-associated outcomes with psychostimulant exposure. Their analyses suggested increased pre-eclampsia risk with early stimulant exposure and increased preterm-birth risk when treatment continued later in pregnancy [16]. Different exposure windows, outcomes and comparison groups explain why these findings cannot be compressed into one statement that the medicine is either “safe” or “unsafe” in pregnancy.
The selected UK SmPC does not recommend use during pregnancy and addresses planning pregnancy and the choice between breast-feeding and therapy; dexamfetamine enters human milk [1]. Individual clinical decisions require the relevant product information and specialist assessment.
For pharmacovigilance follow-up, obtain gestational timing, actual product, dose, indication, co-medications, maternal conditions and pregnancy and infant outcomes. Record prescribed exposure separately from nonmedical use. Where only a dispensing record is available, acknowledge that it does not prove ingestion. A negative malformation study should not be used to dismiss a report concerning prematurity, neonatal symptoms or a different endpoint.
Translating the evidence into pharmacovigilance practice
Dexamfetamine's safety assessment is strongest when the product and event are both described precisely. The following is a recommended medical follow-up framework, rather than a list of extra legal ICSR validity criteria.
| Assessment domain | Information to seek | Why it changes interpretation |
|---|---|---|
| Product identity | Pack name, active substance, salt, strength, release form, country | Distinguishes dexamfetamine from related medicines |
| Actual exposure | Dose times, changes, missed or extra doses, route, last dose | Tests the chronology and potential changed exposure |
| Clinical event | Symptoms, diagnosis, investigations, seriousness and outcome | Separates a reported complaint from a confirmed syndrome |
| Baseline | Prior symptoms, growth measurements, relevant diagnoses | Helps identify what changed after treatment |
| Other exposures | Prescribed, OTC and nonmedical substances | Supports interaction and alternative-cause assessment |
| Treatment response | Action taken and subsequent clinical course | Informs dechallenge interpretation without requiring rechallenge |
Begin with the information available; do not delay initial regulatory handling while waiting for every desirable field. EMA's current GVP framework addresses case management, signal management and quality-system responsibilities, with its published implementation material for ICH E2D(R1) also relevant [17]. Exact reporting duties depend on the case and jurisdiction. A follow-up recommendation in this article is not a new reporting deadline.
The source narrative should retain the distinction between what happened and why somebody thinks it happened. For example, “the patient reported severe insomnia after the afternoon dose” is different from “the medicine caused a manic episode.” Both may eventually belong in the case, but only if their sources and supporting evidence are clear. See also case narrative writing and listedness, expectedness and reference safety information.
Hypothetical application: a formulation switch
An adult reports palpitations and poor sleep after replacing lisdexamfetamine with dexamfetamine. The first follow-up should establish the prescribed and dispensed products, dose schedules and whether both were taken during the transition. Seek the timing of palpitations, measured pulse, any diagnosis and concomitant treatments.
This hypothetical scenario does not establish an incorrect conversion or an adverse reaction. It illustrates why “same active moiety eventually reaches the circulation” does not establish equivalent administration. Record the treating clinician's actions and outcome; avoid proposing a deliberate rechallenge to strengthen causality.
Hypothetical application: behavioural deterioration in a child
A parent reports irritability, reduced eating and deteriorating school behaviour during treatment. Obtain baseline behaviour, dose and administration history, dated weight measurements, sleep information and observations from the treating team. Clarify whether symptoms occur throughout the day, after a dose or as benefit wears off.
The case may contain several events with different timelines. Coding everything as “ADHD worsened” can obscure a new symptom; coding everything as a psychiatric drug reaction can erase the underlying disorder. The purpose of follow-up is to preserve those distinctions, not to predetermine the conclusion.
Hypothetical application: pregnancy outcome
A report describes preterm delivery after stimulant exposure. Confirm the actual medicine and gestational periods, obstetric diagnoses, other treatments and neonatal outcome. Do not substitute the reassuring malformation findings for an assessment of preterm birth. Conversely, an adverse outcome alone does not establish that the drug caused it.
These examples are teaching scenarios, not actual patient reports or published inspection findings.
Signal evaluation, governance and inspection evidence
At aggregate level, maintain enough product detail to examine relevant subgroups without fragmenting the data beyond usefulness. An exploratory review might distinguish direct dexamfetamine exposure, prodrug exposure and mixed-salt products, then test whether any apparent difference survives medical review and differences in prescribing context. This is a proposed analytical approach, not a mandatory regulator-prescribed stratification.
Report counts alone cannot establish incidence. Before interpreting an increase, examine case quality, duplicates, stimulated reporting, product-name ambiguity, changes in use and the availability of a meaningful exposure denominator. Literature findings should be assessed for applicability to the product population and endpoint, rather than copied into a risk register as interchangeable class facts.
For governance, the QPPV should be able to follow the reasoning from source evidence to the documented decision. An illustrative inspection question is whether a serious psychiatric case can be traced through intake, follow-up, medical assessment, aggregate review and any subsequent action. Another is whether the company can identify which product-information version supported an expectedness decision. These are questions about system effectiveness, not manufactured findings [17].
A proportionate review file can bring together the exact regulatory source, the relevant clinical evidence, the assessed uncertainty, the decision owner and the rationale for action or continued monitoring. Where a signal does not lead to a label change, the record should explain the reasoning; absence of a change is not itself evidence that the issue was ignored.
A practical review checklist is:
- Confirm the administered active substance, presentation and country.
- Verify the applicable label and distinguish it from treatment guidance.
- Reconstruct exposure and event chronology, preserving baseline symptoms.
- Separate direct evidence from class, prodrug and formulation evidence.
- Document alternative explanations and the limits of available follow-up.
- Trace the case and aggregate assessment to the resulting decision.
Key Takeaways
Dexamfetamine has a long therapeutic history but a product-specific contemporary safety context. Clinical trials support benefit in defined populations; they do not establish universal interchangeability or settle every long-term question. The most useful safety assessment connects the exact medicine, actual exposure and clinical phenotype while distinguishing label warnings, observational associations and professional interpretation.
Regional authorisation differences, prodrug comparisons and the limitations of the 2026 follow-up study all reinforce the same principle: evaluate the evidence at the level at which it was generated. Accurate case identification and transparent reasoning make that principle operational.
References
- Medice UK. Amfexa 5 mg Tablets / Dexamfetamine Sulfate Medice 5 mg Tablets: Summary of Product Characteristics. emc updated 5 May 2026. https://www.medicines.org.uk/emc/product/5004/smpc
- DailyMed. Dextroamphetamine Sulfate Tablets, USP CII. Bryant Ranch Prepack label; revised August 2025, version 3, effective 26 August 2025; accessed 23 October 2026. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=54b122b0-2ec8-43c9-86e8-a3538a83c776&type=display
- Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present—a pharmacological and clinical perspective. J Psychopharmacol. 2013;27:479–496. https://doi.org/10.1177/0269881113482532
- Freyberg Z et al. Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain. Nat Commun. 2016;7:10652. https://doi.org/10.1038/ncomms10652
- Dolder PC et al. Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects. Front Pharmacol. 2017;8:617. https://doi.org/10.3389/fphar.2017.00617
- Efron D, Jarman F, Barker M. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100:e6. https://doi.org/10.1542/peds.100.6.e6
- Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100:662–666. https://doi.org/10.1542/peds.100.4.662
- Ramtvedt BE et al. Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials. J Child Adolesc Psychopharmacol. 2013. https://doi.org/10.1089/cap.2012.0085
- Poulton A et al. A randomised open-label comparison of dexamphetamine and methylphenidate in children with attention deficit hyperactivity disorder (ADHD): symptom response, adherence and weight impact over 12 months. J Paediatr Child Health. 2026;62:1621–1629. https://doi.org/10.1111/jpc.70487
- Paterson R et al. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry. 1999;33:494–502. https://doi.org/10.1080/j.1440-1614.1999.00590.x
- NICE. Attention deficit hyperactivity disorder: diagnosis and management (NG87). Recommendations, including 1.7.14. https://www.nice.org.uk/guidance/ng87/chapter/recommendations
- Cooper WO et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896–1904. https://doi.org/10.1056/NEJMoa1110212
- Moran LV et al. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019;380:1128–1138. https://doi.org/10.1056/NEJMoa1813751
- FDA. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. Drug Safety Communication, 11 May 2023. https://www.fda.gov/drugs/drug-safety-communications/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions
- Huybrechts KF et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the International Pregnancy Safety Study Consortium. JAMA Psychiatry. 2018;75:167–175. https://doi.org/10.1001/jamapsychiatry.2017.3644
- Cohen JM et al. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol. 2017. https://doi.org/10.1097/AOG.0000000000002362
- EMA. Good pharmacovigilance practices. Current module and implementation index, including Modules I, III (Rev. 2), VI (Rev. 2), IX (Rev. 1), and ICH E2D(R1) implementation notice; accessed 23 October 2026. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp
Regulatory Note
Educational review dated 23 October 2026. Dexamfetamine is the INN spelling; dextroamphetamine is the corresponding US name. National product information, clinical guidelines, clinical-study evidence and recommended operational practice have different authority and scope. The UK and selected US labels discussed here do not establish identical authorisation elsewhere. The US reference is explicitly an August 2025 revision accessed during this review, rather than a claim that every US label has the same revision. Consult the current product-specific information for clinical decisions. Hypothetical cases and inspection questions are illustrative.